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Respiratory syncytial virus (RSV) is a major cause of respiratory illness in infants, immunocompromised
patients, and the elderly. New antiviral agents would be important tools in the treatment of acute RSV disease.
RSV encodes its own RNA-dependent RNA polymerase that is responsible for the synthesis of both genomic
RNA and subgenomic mRNAs. The viral polymerase also cotranscriptionally caps and polyadenylates the RSV
mRNAs at their 5 and 3 ends, respectively. We have previously reported the discovery of the first nonnucleo-
side transcriptase inhibitor of RSV polymerase through high-throughput screening. Here we report the design
of inhibitors that have improved potency both in vitro and in antiviral assays and that also exhibit activity in
a mouse model of RSV infection. We have isolated virus with reduced susceptibility to this class of inhibitors.
The mutations conferring resistance mapped to a novel motif within the RSV L gene, which encodes the
catalytic subunit of RSV polymerase. This motif is distinct from the catalytic region of the L protein and bears
some similarity to the nucleotide binding domain within nucleoside diphosphate kinases. These findings lead
to the hypothesis that this class of inhibitors may block synthesis of RSV mRNAs by inhibiting guanylylation
of viral transcripts. We show that short transcripts produced in the presence of inhibitor in vitro do not contain
a 5 cap but, instead, are triphosphorylated, confirming this hypothesis. These inhibitors constitute useful tools
for elucidating the molecular mechanism of RSV capping and represent valid leads for the development of
novel anti-RSV therapeutics.
Human respiratory syncytial virus (RSV) is the leading cause
of severe lower respiratory tract infection in infants and a
major cause of morbidity and mortality in elderly and immu-
nocompromised adults (8, 10). Only two products are approved
for treatment or prevention of RSV infection: the nucleoside
analog ribavirin, available for treatment of hospitalized pa-
tients, and the monoclonal antibody palivizumab (Synagis), for
prophylaxis (14, 30). However, these agents have significant
limitations, and new therapeutics with improved efficacy and
safety are needed (22, 29).
Viruses in the Mononegavirales order, such as respiratory
syncytial virus (RSV), have a nonsegmented negative sense
RNA genome which serves as template for transcription of
subgenomic mRNAs and the positive sense replication inter-
mediate. The enzyme responsible for both of these processes,
the RSV RNA-dependent RNA polymerase, is comprised of at
least five viral components including the genomic RNA and
the L, N, P, and M2-1 proteins (8). Together these components
form a ribonucleoprotein (RNP) complex that is capable of de
novo initiation and synthesis of positive and negative sense
genomic RNA (“replicase” activity) as well as subgenomic
mRNAs (“transcriptase” activity). The RNP complex isolated
from RSV-infected cells has been shown to possess an RNA-
dependent RNA polymerase (RdRp), mRNA polyadenylation,
and mRNA capping activities in vitro (4, 5, 27). Multiple pro-
tein-protein and protein-RNA interactions mediate the assem-
bly and activity of this complex (12, 13, 16, 20, 21, 26, 33, 38,
41). Thus, the RSV RNP is a complex that is rich in potential
antiviral targets.
We along with others have previously reported the prepara-
tion of RNP that is capable of synthesis of RSV mRNAs in
vitro (4, 17, 18, 27). We have used such a crude enzymatic
activity to develop an assay that specifically measures the syn-
thesis of RSV transcripts in vitro through capture of the
mRNA poly(A) tails (27). A novel inhibitor of RSV polymer-
ase was discovered through screening of this poly(A) capture
assay (Fig. 1, compound A). Inhibition by this compound was
noncompetitive with nucleotides in vitro and prevented the
replication of RSV in cell culture assays (27). Here we show
that compounds with greater potency against RSV transcrip-
tase are also more potent inhibitors of viral replication in cell
culture and have activity in a mouse model for RSV infection
(Fig. 1, compounds B to E, and Table 1). Isolation and char-
acterization of virus with reduced susceptibility to this class of
inhibitor have led to the identification of a new motif in the
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RSV L protein. We show that inhibition of mRNA guanylyla-
tion by these small molecules can prevent the synthesis of
full-length RSV transcripts. We believe that this is a unique
mechanism of action for the inhibition of a viral transcriptase
and that this mechanism is most likely responsible for their
antiviral activity in cells and animals.
MATERIALS AND METHODS
Animals, cells, and viruses. Cell culture reagents and media were obtained
from Gibco BRL. BALB/c mice were purchased from Charles Rivers Laborato-
ries. HEp-2 cells and the A2 and Long strains of RSV were from the American
Type Culture Collection. HEp-2 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 g/ml streptomycin sulfate, and 100 g/ml kanamycin sulfate at
37°C in an atmosphere of 5% CO2. Virus stocks were grown in HEp-2 cells, and
virus titers were determined by a standard plaque assay.
RSV polymerase assays. Isolation of RSV RNP from virus-infected HEp-2
cells, transcription reactions, and RSV poly(A) capture assay were described
previously (27). Compounds were tested in serial threefold dilutions. Nonlinear
regression analysis using SAS software (SAS Institute, Cary, NC) was employed
to determine the inhibitor concentration needed to give 50% reduction of en-
zyme activity (IC50).
Analysis of RNA products by gel electrophoresis. Transcription reactions were
performed as previously described (27) but contained 15 Ci of [-33P]CTP
(3,000 Ci/mmol) or 50 nM CTP. RNA products were incubated with 5 g
oligo(dT)15 and then with 7 U of RNase H to remove poly(A) tails. The reactions
were stopped with 80 g of tRNA and 20 mM EDTA, and the transcripts were
extracted with Trizol LS (Invitrogen) as per the manufacturer’s protocol. Tran-
scripts were treated with formamide and run on a 6% polyacrylamide–7 M urea
gel and detected using a Storm PhosphorImager (Molecular Dynamics).
Analysis of cap structure by HPLC. RSV mRNA was made in in vitro tran-
scription reactions as previously described (27), except reaction mixtures con-
tained 5 M S-adenosylmethionine (SAM), 400 M ATP, 400 M UTP, 10 M
CTP, 50 M GTP, and 100 Ci of [-32P]GTP (3,000 Ci/mmole; NEN) with or
without 100 M compound E in 4% dimethyl sulfoxide. Incubation proceeded
for 6 h at 30°C. RNA was purified on ProbeQuant G-50 columns (Amersham).
32P-labeled NS2 RNA was prepared with the MaxiScript Kit (Ambion) using a
102-bp DNA template corresponding to the 5 end of the RSV NS2 open reading
frame in the presence of 100 M GTP and 70 Ci of [-32P]GTP (3,000 Ci/
mmole) and then purified on G-50 columns and precipitated with 0.8 M LiCl, 100
g/ml glycogen, and 50% isopropanol at20°C; samples were washed twice with
ice-cold 70% ethanol, dried, and resuspended in 4 mM potassium phosphate, pH
5.5. Samples were digested with 0.1 mg/ml nuclease P1 or 5 U of RNase T2.
T2-digested samples were subsequently digested with 5 g of calf intestinal
phosphatase (CIP; Roche) in 20 mM Tris-Cl, pH 8.5, 100 mM NaCl. Samples
were analyzed on a Partisil 5 SAX column using a gradient from 4 to 1,000 mM
KPO4, pH 5.5, over 60 min at 1 ml/min (37). Products containing 32P were
detected on a Berthold radioactivity monitor.
Antiviral assay. Antiviral activity was assessed in an enzyme-linked immu-
nosorbent assay (ELISA) as described previously (25, 27) using an anti-RSV F
monoclonal antibody (Serotec MCA 490, clone B016). HEp-2 cells in DMEM
containing 2% FBS were infected with RSV Long at a multiplicity of infection
(MOI) of 0.1 and incubated for 48 h in the presence or absence of serial dilutions
of inhibitors. Compound solutions in dimethyl sulfoxide (final concentration,
1%) were filtered through 0.22-m-pore-size Star LB filters (Costar), and
concentrations were verified by high-pressure liquid chromatography (HPLC).
The concentration of compound required to inhibit virus replication by 50%
(EC50) was calculated as specified for the IC50 determinations. Cytotoxicity was
determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay (25) and results were expressed as 50% cytotoxic concentra-
tions (CC50).
Isolation and sequencing of resistant viruses. Two resistant viral isolates, Cr-1
and Cr-19, were selected by serial passage of RSV Long at an MOI of 1 in the
presence of 2 to 4 M compound C on confluent HEp-2 cells. Likewise, the
resistant isolate Br-1 was selected at an MOI of 0.1 in the presence of 20 M
compound B. In each case, control viruses were grown in parallel to the same
passage without compound. All resistant isolates were plaque purified in the
presence of inhibitor. RNA was isolated from viral particles obtained from cells
infected with the various resistant viruses using Trizol LS. cDNA was prepared
by reverse-transcription PCR for DNA sequence determination, using Super-
script II (Invitrogen) according to the manufacturer’s protocol.
Cloning and production of RSV L with an I1381S substitution. Standard
molecular biology techniques (39) were employed for the construction of all
plasmids [pMini-RSV-Luc3, pCR-N12, pCR-P29, pcDNA-M2-1, and wild-type
pcDNA-L(Long)] for expression of RSV proteins and minigenomic RNA. To
produce mutated pcDNA-L(I1381S), the L genes were amplified by PCR, cloned
using the Echo cloning system (Invitrogen), and recombined with the mamma-
lian expression vector pcDNA3.1E.
Minigenome reporter assay. HEp-2 cells were plated at 250,000 cells per
12-well dish in DMEM–10% FBS and incubated overnight. Cells were infected
with vaccinia vTF7.3 at an MOI of 5 PFU per cell in Opti-MEM containing 2%
FBS, followed immediately by cotransfection with 200 ng of pLuc3, 200 ng of
pN12, 100 ng of pP29, 50 ng of pM2, and 50 ng of either pcDNA-L(Long)
wild-type or I1381S plasmids using Lipofectamine Plus (Invitrogen) according to
the manufacturer’s directions. At 16 h posttransfection the medium was re-
FIG. 1. Molecular structure of RSV polymerase inhibitors. Com-
pounds were synthesized using a method similar to that initially de-
scribed for compound A (1). Details will be published elsewhere (B.
Simoneau, unpublished data).
TABLE 1. Biological profile of RSV polymerase inhibitors as
compared to ribavirina
Compound PolymeraseIC50 (M)
Antiviral
EC50
(M)
Cytotoxicity
CC50 (M)
Selectivity
(CC50/
EC50)
Mouse model
log titer
reduction
(N)b
B 10.4 2.1 16 8 ND
A 4.5 1.3 7.7 6 ND
C 0.88 0.25 7.6 30 0.12 (6)
E 0.66 0.10 10.7 107 0.38* (12)
D 0.089 0.021 8.4 400 0.60* (12)
Ribavirin ND 6.9 200 29 0.04 (12)
a RSV polymerase assays were performed using the poly-A capture assay and
antiviral activity was measured by ELISA. Cytotoxicity was determined using an
MTT assay. Values shown are the average of at least three determinations.
b The effect of inhibitors on RSV lung titers in mice was determined using the
number of animals shown in parentheses. Vehicle-treated animals (n  24)
exhibited lung titers of 3.52  0.04 log. The doses administered were as follows:
compound C, 0.4 mg/kg/day; compound D, 0.4 mg/kg/day and compound E, 4.1
mg/kg/day. Ribavirin (Sigma) was administered at a dose of 10 mg/kg/day in
vehicle. *, significantly different from vehicle; ND, not determined.
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moved, and the cells were incubated for 2 h with 2 g per ml actinomycin D. The
cells were washed with phosphate-buffered saline (PBS) and incubated in Opti-
MEM containing 2% FBS with or without compound. All incubations were
conducted at 37°C in 5% CO2 humidified air. Cells were lysed 40 h posttrans-
fection, and luciferase activity was assayed using the Promega luciferase assay
system according to manufacturer’s protocol.
Murine RSV model. Female BALB/c mice (5 weeks of age; 14 to 16 g) were
infected intranasally with RSV A2 (5,000 syncytia forming units). RSV polymer-
ase inhibitors or ribavirin was dissolved in vehicle [saline 0.9% (wt/vol) and 2.1%
(wt/vol) Tween-80, pH 7] at the highest soluble concentrations. Treatments with
RSV polymerase inhibitors or ribavirin were administered intranasally 3 and 6 h
following inoculation with virus and then three times per day for 3 days. Lung
viral titers at day 4 postinfection were determined by plaque assay (34). Statistical
differences were determined by analysis of variance, followed by a Student-
Newman-Keuls test for multiple comparisons, with P 	 0.05 considered statis-
tically significant.
Bioinformatics analyses. Polymerase sequences from eight Mononegavirales
viruses (Ebola, measles, mumps, Newcastle disease virus, rabies, RSV, Sendai,
and vesicular stomatitis virus) were used with the algorithm MEME (Multiple
EM for Motif elicitation; http://meme.sdsc.edu/meme/website/intro.html) (2) to
find conserved motifs. Use of the full-length sequences of these eight poly-
merases led to the identification of the motifs already known to play a role in the
polymerase (A to D) (32, 36). Further subdivision of the sequences into regions
N-terminal and C-terminal to these known motifs led to the identification of
other motifs (see Fig. 3 for motifs 1N to 9N, 1C to 10C, and methyltransferase;
detailed alignments showing the positions of all motifs are available upon re-
quest). These motifs were named based on their level of conservation, with 1
being the most conserved and 10 being the least conserved. MEME creates a
profile (based on the frequency of each amino acid at each position) of the
various motifs it finds, and these profiles can then be used to search other
databases for their occurrence in other proteins. This search was undertaken with
each of the profiles from the various motifs using the MAST (motif alignment
search tool; http://meme.sdsc.edu/meme/website/intro.html) algorithm. Only
motif 5C led to interesting hits other than Mononegavirales polymerases, namely,
multiple plant nucleoside diphosphate kinases (NDKs).
Secondary structure analysis was performed by submitting either the RSV or
the human NDK sequence to the Jpred server (9) (http://www.compbio.dundee
.ac.uk/www-jpred/).
RESULTS
Lead optimization and antiviral activity. We have previously
discovered a nonnucleoside inhibitor of the RSV RdRp activ-
ity via high-throughput screening of our corporate compound
collection using a novel RSV polymerase poly(A) capture as-
say (Fig. 1, compound A structure) (27). Lead optimization
studies have resulted in more potent analogs of compound A
(Table 1 and Fig. 1). In particular, compound D was 51 times
more potent than compound A in the RSV polymerase assay.
In addition, this series of compounds exhibited significant an-
tiviral activity with the same rank order of potency in a cell-
based ELISA virus replication assay against both Long (Table
1) and A2 (data not shown) RSV strains. Significantly, com-
pound D was over 300 times more active than ribavirin, with an
EC50 of 21 nM and a selectivity index of 400. RSV polymerase
inhibitors were also active in viral plaque reduction assays, with
EC50s typically twofold higher than in ELISA (data not
shown). The inhibitory effect of RSV polymerase inhibitors
was lost when added 9 to 10 h postinfection (data not shown),
consistent with the effect of compounds on postadsorption/
fusion events and the onset of viral transcription (8). The
potential for antiviral activity in vivo was assessed by testing
selected RSV polymerase inhibitors in female BALB/c mice
infected with RSV strain A2. A significant reduction in pul-
monary titers of RSV was observed with compounds D and E
after intranasal administration of these two compounds (Table
1). In contrast, topically applied ribavirin was ineffective at
reducing viral lung titers. This lack of efficacy correlates with
previous observations that a reduction of lung viral titers in
mice by ribavirin is dependent on the amount of viral inoculum
employed (7). That is, the higher the inoculum is, the greater
the reduction of lung viral titers at a given dose of drug. In
contrast, the efficacy of compounds D and E shown here indi-
cates that inhibition of RSV polymerase can lead to reduction
of RSV replication in vivo.
Mechanism of action of RSV polymerase inhibitors. To con-
firm that the compounds inhibited the RSV polymerase within
cells, selected compounds were tested in an RSV minigenome
assay (23, 24, 45) which measures viral RNA-dependent RNA
polymerase activity independently of viral replication. The
RSV polymerase activity is reconstituted via cotransfection of
T7-vaccinia virus-infected HEp-2 cells with T7-based plasmids
that express RSV N, P, M2-1, and L genes, along with a
minigenome plasmid resulting in luciferase activity in the ab-
sence of any other RSV proteins. Consistent with inhibition of
RSV transcription, compounds C and D inhibited luciferase
activity in this assay, with EC50 values of 450 and 33 nM,
respectively.
In our initial characterization of an inhibitor of this class
(27), we have already shown that inhibition by compound A
was noncompetitive versus nucleotides. Additionally, we
FIG. 2. Effect of compound A on RSV transcripts. Transcription
reactions were performed with 50 nM [-33P]CTP in the presence of 0
to 75 M of compound A. Denatured transcripts were run on a 6%
polyacrylamide–7 M urea gel. The bracket indicates the position of
small RNA transcripts produced only in the presence of compound A.
The asterisk indicates nonspecific products by contaminating nucleoti-
dyl transferase. The relative migration of 50- and 100-nucleotide (nt)
markers and that of RSV transcripts are indicated.
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showed that the synthesis of all major RSV mRNA species
produced by viral RNP in vitro was equally inhibited by this
compound (27). Interestingly, when RNA products produced
by in vitro transcription reactions were analyzed on 6% poly-
acrylamide–7 M urea gels, shorter heterogeneous RNAs were
observed only in the presence of compound, especially when
low concentrations of [-33P]CTP (Fig. 2) were used. More-
over, in a standard DE81 filter binding assay, compound A
achieved less than 50% inhibition at the highest concentration
tested (27), a result consistent with the production of short
RNA species which would be retained on DE81 filters and
mask the inhibition. Although there are alternative explana-
tions for the appearance of short RNAs in the presence of
inhibitor, such as increased degradation due to lack of poly(A)
tails or increased synthesis of the leader RNA, it is plausible
that compound A caused iterative abortive mRNA transcrip-
tion leading to increased amounts of short RNA species.
Isolation of inhibitor-resistant RSV and identification of the
RNP subunit targeted by the inhibitor. To identify the molec-
ular target of the inhibitors, three independent drug-resistant
RSV mutants were selected in the presence of the inhibitors B
and C. Resistant viral isolates were obtained after 5 passages
FIG. 3. Mapping of RSV polymerase inhibitor resistance mutations to a central region of RSV L having similarity to NDKs. (A) Single amino
acid changes in three resistant RSV isolates mapped to a central region of RSV L at amino acids 1269, 1381, and 1421. The highlighted motifs
have known functions for polymerase activity (black boxes) (32) and methyltransferase activity (yellow diamonds) (11). (B) The L protein
sequences from the indicated viruses were used as input for the program MEME. The position of the starting amino acid is in parentheses.
Alignment of the 5C and 1C motifs (blue boxes) is shown with the similar region in human NDK (P22392). This NDK sequence (NDKB HUM)
is colored according to the conservation of residues found in an alignment of the following NDKs for which an X-ray structure was obtained:
P52174, P22887, P15266, and P22392. Residues in red are invariant, residues in blue are highly conserved, and those in green are weakly conserved.
Arrows indicate residues that contact nucleotides in NDKs: arginine and threonine contact the 
-phosphate and histidine binds the -phosphate
(31). The circled residue in the RSV sequence is mutated in Cr-19. NDV, Newcastle disease virus; VSV, vesicular stomatitis virus; Pred. S.S.,
predicted secondary structure; 1NUE (X-ray), experimental secondary structure according to the 1NUE PDB record; H, helix; E, extended.
13108 LIUZZI ET AL. J. VIROL.
 o
n
 M
ay 18, 2016 by UNIV DU QUEBEC A M
ONTREAL
http://jvi.asm.org/
D
ow
nloaded from
 
with compound C and after 11 passages with compound B.
Plaque-purified resistant isolates Cr-1, Cr-19, and Br-1 profiled
against selected inhibitors using the ELISA RSV replication
assay were approximately eight-, four- and threefold resistant
to compound C, respectively. All three isolates were cross-
resistant to other RSV polymerase inhibitors within the same
chemical class, but resistant viruses were still sensitive to riba-
virin, indicating a distinct antiviral mechanism of action (data
not shown). Furthermore, all mutant viruses replicated with
near wild-type growth kinetics, and titers close to wild-type
virus were obtained (data not shown). The RSV N, P, M2-1,
and L genes from the resistant isolates were amplified by
reverse-transcription-PCR and sequenced in order to deter-
mine which subunit of the RNP complex was targeted by the
inhibitors. Each of the three resistant strains harbored a dif-
ferent single nucleotide substitution in the L gene, resulting in
one of the following amino acid changes: I1381S, E1269D, or
L1421F (Fig. 3A). No mutations in the other RNP subunit
genes from the inhibitor-resistant isolates were detected when
compared to virus passaged in the absence of inhibitor (data
not shown). Next, the L genes from both wild-type RSV Long
and resistant isolate Cr-1 were tested in the minigenome assay
to verify that the mutation was responsible for reduced sus-
ceptibility. As shown in Table 2, the inhibitory activity of com-
pounds C and D was reduced by eight- and ninefold, respec-
tively, when they were tested in the presence of the mutated L
gene. This loss of sensitivity was similar to that seen in the RSV
replication assay or in in vitro transcription assays using RNP
isolated from HEp-2 cells infected with Cr-1. These results
confirm that the amino acid substitution I1381S in the L pro-
tein reduced RSV sensitivity to these compounds and suggest
that this class of RSV polymerase inhibitors may bind to a
specific region of the L protein, defined in part by a 152-amino-
acid segment (Fig. 3A) that encodes the three resistance mu-
tations.
Identification of a new motif in the RSV L. In an attempt to
assign a function to the putative inhibitor-binding region, we
used MEME (2) to identify regions conserved within L pro-
teins from closely related viruses of the Mononegavirales order.
Several motifs were identified, including those conserved
among polymerases (32, 36) and methyltransferases (11) (M.
Cartier, unpublished data). Using the MAST (3) algorithm to
search the public protein database with each motif’s MEME
profile revealed that two motifs (Fig. 3B, motifs 5C and 1C)
close to the region containing the three resistance mutations
showed some similarity to a region in NDKs (31), important
for nucleotide binding, suggesting that this region of the L
proteins might also participate in nucleotide binding. Since
RSV polymerase inhibitors increased the appearance of short
RNAs (Fig. 2), we hypothesized that the inhibitors might pre-
vent cotranscriptional capping of viral mRNAs required for
full elongation of transcripts (5, 8). Although the precise mech-
anism of mRNA capping in viruses of the Mononegavirales
order is not known (40), perturbations in cap formation can
affect downstream transcriptional events for some of these
viruses (19, 42). Cap methylation is not essential for RSV
transcription since S-adenosylhomocysteine does not affect
transcription although it does inhibit SAM-dependent methyl-
ation of RSV transcripts (5) (M. Liuzzi, unpublished results).
It was therefore more likely that RSV polymerase inhibitors
affected cotranscriptional guanylylation of mRNAs.
Effect of RSV polymerase inhibitors on RSV mRNA cap
formation. Prior to evaluating the effect of inhibitors on RSV
mRNA cap formation, we assessed whether our RSV polymer-
ase preparation was capable of catalyzing the formation of
mRNA caps. For this, RSV transcripts were prepared in vitro
in the presence of [3H]SAM and purified on Oligotex resin.
Labeled transcripts were then treated with RNase T2, and the
digested material was analyzed by strong anion exchange
HPLC. As a reference, the expected products from the various
enzymatic treatments used in these experiments on different
RNAs are indicated in Table 3. Digestion of RSV transcripts
with RNase T2 produced two peaks at 23 and 25 min (Fig. 4).
The elution patterns of these two peaks were consistent with
cap 0 (7mGpppGp) and cap 1 (7mGpppGmpGp) structures, as
determined by elution profiles of standards produced by
RNase T2 digestion of NS2 RNA produced with T7 RNA
polymerase and capped with vaccinia virus capping enzyme in
the presence of [-32P]GTP and cold SAM (Fig. 4C). Interest-
ingly, and contrary to a previous report by Barik (5), the RSV
RNP produced both cap 0 and cap 1 structures, and the rela-
tive abundance of the two caps could be modulated by the
concentration of SAM used in the experiment: in the presence
of 0.2 M SAM the transcripts were predominantly cap 0, but
in the presence of 10 M SAM they were mostly cap 1 (Fig. 4A
and B). Combined, these results indicate that our RSV poly-
TABLE 2. Resistance profile of RSV polymerase inhibitors
Compound PolymeraseIC50 (M)a
Antiviral
EC50
(M)b
Minigenome
EC50 (M)c
C 6.2 (7) 2.0 (8) 3.6 (8)
D 1.1 (12) 0.40 (19) 0.30 (9)
a RSV polymerase poly-A capture assays were performed with RSV RNP
isolated from cells infected with RSV Long Cr-1.
b Antiviral activity against RSV Cr-1 was measured by ELISA.
c Activity in the minigenome assay was measured using the mutated pcDNA-
LI1381S plasmid. Values in parenthesis indicate the n-fold increase compared to
wild-type (mutant/WT).
TABLE 3. Expected products from enzymatic treatment of capped and uncapped RNAs
Enzyme
RNA
Cap0 Cap1 Uncapped RNA
None 7mGpppGpGpGp. . . 7mGpppGmpGpGp. . . pppGpGpGp. . .
Ribonuclease T2 7mGpppGp  3-GMP 7mGpppGmpGp  3-GMP pppGp  3-GMP
Ribonuclease T2 plus CIP 7mGpppG  guanosine  Pi 7mGpppGmpG  guanosine  Pi Guanosine  Pi
Nuclease P1 7mGpppG  5-GMP 7mGpppGm  5-GMP pppG  5-GMP
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merase preparation is fully capable of guanylylating and meth-
ylating RSV mRNAs to form both cap 0 and cap 1 structures.
To investigate whether polymerase inhibitors affected RSV
mRNA cap formation, we labeled the transcripts with
[-32P]GTP in the absence and presence of compound E. Since
all RSV transcripts start with a guanine nucleotide (8), we
reasoned that using labeled GTP instead of [3H]SAM would
allow the determination of the status of the 5 end of the
transcripts whether they were modified by a cap or not. La-
beled transcripts were isolated and treated with either RNase
T2, alone or in combination with CIP or with nuclease P1
(NP1), and the digested material was then analyzed by strong
anion exchange HPLC (Fig. 5) (Table 3 shows the activities
of these enzymes in relation to the status of the 5 end of
transcripts). In the absence of inhibitor, digestion with RNase
T2 produced a large peak at 20 min, corresponding to nu-
cleoside monophosphates, and, as expected, two smaller peaks
at 30 and 33 min corresponding to cap 0 (7mGpppGp) and cap
FIG. 4. RSV polymerase preparations produce both cap 0 and cap 1. HPLC analyses of RNase T2-digested RNA on a Partisil 5 SAX column
using a gradient of potassium phosphate (pH 5.5) from 4 to 800 mM. (A) Capped RSV RNA prepared by in vitro transcription in the presence
of 0.2 M [3H]SAM and purified on Oligotex resin followed by treatment with RNase T2 and analysis by HPLC. (B) Capped RSV RNA prepared
by in vitro transcription in the presence of 10 M [3H]SAM was treated as in panel A. (C) Capped NS2 RNA was produced by in vitro transcription
using T7 RNA polymerase followed by incubation in the presence of vaccinia virus capping enzyme and [-32P]GTP. This RNA was then purified
on an RNeasy column, treated with RNase T2, and analyzed as in panel A. The peaks labeled cap 0 and cap 1 refer to
7mGpppGp and
7mGpppGmpGp, respectively.
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1 (7mGpppGmpGp) structures (Fig. 5A) in comparison to stan-
dards run under identical conditions (Fig. 6). In contrast to
the cap 0 and cap 1 species observed in the absence of RSV
polymerase inhibitor, in the presence of compound E, a dif-
ferent peak appeared at 50 min (Fig. 5B). Additional treat-
ment with CIP eliminated this unknown peak, indicating the
presence of unprotected phosphate groups (Fig. 5C). Lastly,
NP1 digestion of RSV transcripts made in the presence of
inhibitor yielded primarily GTP and some GDP (Fig. 5D). This
result suggested that the short transcripts were phosphorylated
and that the structure of the peak at 50 min might be
guanosine tetraphosphate (pppGp). As a control, an uncapped
RNA synthesized with T7 RNA polymerase that was digested
with either RNase T2 or NP1 to produce pppGp and GTP,
respectively, verified this hypothesis (Fig. 4E and F). Addition-
ally, a plot of the charge-to-mass ratio of several standards
compared to HPLC retention time under identical conditions
supports the idea that the peak at 50 min corresponds to
pppGp (Fig. 6D). Altogether, these results indicate that RSV
polymerase inhibitors prevent mRNA guanylylation.
DISCUSSION
The RSV polymerase is comprised of at least five viral com-
ponents which together form an RNP complex, with RdRp
activity required for the synthesis of both viral genomic RNA
(replicase activity) and subgenomic mRNAs (transcriptase
activity). As opposed to the viral replication products, RSV
mRNAs are cotranscriptionally capped (i.e., guanylated and
methylated) at their 5 ends and polyadenylated at their 3 end
by the RNP complex (4, 5, 8, 27, 44). These modifications are
necessary for translation of the viral mRNAs by the host pro-
tein synthesis machinery. The RNP complex functions exclu-
sively in the cytoplasm of the RSV-infected cells (8, 40). Since
the host proteins responsible for the capping of mRNAs are
located in the nucleus of the cell, capping of viral mRNAs by
FIG. 5. RSV polymerase inhibitors prevent RSV mRNA guanylylation. RSV transcripts were labeled with [-32P]GTP in the presence or
absence of inhibitor (compound E), digested with nuclease, and analyzed by HPLC as described in the legend of Fig. 4, except that the potassium
phosphate gradient used in these experiments (and in those shown in Fig. 6) was 4 to 1,000 mM, instead of 4 to 800 mM. (A) RNase T2 digestion
of RSV mRNA in absence of inhibitor. (B) RNase T2 digestion of RSV mRNA in presence of inhibitor. (C) RNase T2 and CIP treatment of RSV
mRNA in presence of inhibitor. (D) NP1 digestion of RSV mRNA in presence of inhibitor. (E) T7 polymerase synthesized-NS2 RNA after RNase
T2 digestion. (F) T7 polymerase-synthesized NS2 RNA after NP1 digestion. Cap 0 represents
7mGpppGp and cap 1 represents 7mGpppGmpGp.
Note that although other inhibitors were more potent, compound E was used in this experiment due to better compound solubility. The y axis, in
units of mV, is a measure of radioactivity by the Berthold monitor, which converts radioisotope decay to pulses of electricity (1,000 mV is
approximately 8,500 cpm). The retention time of the peak in panel B varied from 48.3 to 50.9 min over seven experiments, whereas the retention
time of the peak in panel E varied from 48 to 49 min.
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the RNP complex is essential for the synthesis of RSV pro-
teins. These multiple activities of the RSV transcriptase make
it an attractive target in screening for potential antiviral agents.
A recent report of a distinct chemical class of RSV replication
inhibitors with resistance mutations mapping to Y1631 of the L
gene confirms this point (43).
The RSV poly(A) capture assay, described previously (27),
had the potential to detect inhibition at any step of the RSV
FIG. 6. Analyses of labeled and unlabeled cap and nucleotide standards. (A) Unlabeled commercially available standards (as indicated) were
chromatographed on a Partisil 5 SAX column as described in the legend of Fig. 5, except that the peaks were detected by UV absorbance at 254
nm. Each product was analyzed separately in order to determine the identity of the peaks when all standards were chromatographed together as
presented in the panel. (B) Capped NS2 RNA was produced by in vitro transcription using T7 RNA polymerase followed by incubation in the
presence of human capping enzyme (obtained from A. Shatkin, University of Medicine and Dentistry of New Jersey) and [-32P]GTP. The RNA
was purified on an RNeasy column treated with RNase T2 and analyzed as described in the legend of Fig. 5. (C) Capped NS2 RNA prepared with
human capping enzyme, human methyltransferase (obtained from A. Shatkin), and [-32P]GTP was purified on an RNeasy column and analyzed
as in panel B. Note that methylation of the guanylated RNA in panel B is incomplete in panel C. Human methyltransferase only methylates the
capping guanine resulting in cap 0 (35). (D) Plot of retention time from HPLC column (x axis) versus calculated charge/mass ratio (y axis) for
standards from panels A, B, and C. Also included in the plot is the retention time of the product shown in Fig. 5D. Linear regression of the plot
produces the formula shown with R2  0.9382, indicating a reasonable fit of the data points.
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transcription cycle that is required for the synthesis of full-
length polyadenylated mRNAs. Using this assay, we screened
our compound collection, leading to the discovery of a unique
inhibitor of RSV transcription with interesting properties: this
nonnucleoside inhibitor was noncompetitive with nucleotides
but was able to completely inhibit the synthesis of all major
mRNA species in vitro. However, this compound only partially
inhibited RNA synthesis when measured in a nonspecific cap-
ture format such as a DE81 filter binding assay. Consistent
with this observation, short RNAs (	50 nucleotides) were
detected when transcripts produced in the presence of inhibi-
tor were analyzed on polyacrylamide gels. These observations
suggest that inhibition of an early postinitiation step in the
transcription cycle could result in the synthesis of high levels of
short abortive transcripts. A similar interplay between 5 cap-
ping and transcription elongation has been proposed for ve-
sicular stomatitis virus (19, 42).
The synthesis of compounds with greater antiviral potency
or greater selectivity index (CC50/EC50) (Table 1) permitted
the isolation of inhibitor-resistant virus. Mapping of the mu-
tations conferring resistance to inhibitors identified a region in
the central portion of RSV L with similarity to NDKs. These
are ubiquitous proteins that play a role in maintaining the
balance of intracellular nucleotide pools by exchanging gam-
ma-phosphate groups from NTP to NDP. The sequence simi-
larity to NDKs and the partial overlap of the inhibitor resis-
tance mutations to this region of L lead to the hypothesis that
this NDK motif is involved in nucleotide binding, which may be
important for mRNA guanylylation. Unfortunately, we were
unable to show a direct interaction of guanine nucleotides with
the L protein or this portion of the L protein. Although the
Mononegavirales polymerases lack the histidine in motif 1C
that is critical to catalytic function of authentic NDK proteins,
the rest of the 1C motif, in particular, is very well conserved as
Hy-Hy-G-S-Po-T/S (where Hy is hydrophobic and Po is polar).
Therefore, the NDK similarity region of L protein could par-
ticipate in the guanylylation reaction without directly cata-
lyzing the guanine nucleotide exchange reaction. For example,
this region could coordinate the triphosphorylated 5 end of
the nascent transcript and/or the guanine nucleotide for their
interaction in the guanylylation reaction.
Based on the presence of inhibitor resistance mutations
within and near the NDK-similarity region of L, we predict that
inhibitors of RSV transcriptase may bind to the L protein in
this region. Through this interaction, these inhibitors would be
able to prevent the guanylylation of RSV mRNAs. Thus, the
NDK similarity region may be directly or indirectly involved in
mRNA guanylylation.
The data presented here and previously (27) support a
model for RSV transcription where mRNA guanylylation is an
essential step in establishing an efficient transcription elonga-
tion complex. The RSV transcriptase could be pictured as a
complex with separate active sites for polymerization, guany-
lylation, and methylation (or SAM binding) (Fig. 7A). Tran-
scription initiation occurs at a gene start sequence (Fig. 7B and
C), and transcripts are extended in early elongation complexes
(Fig. 7D) until they are about 45 to 50 nucleotides long, the
size of the aborted RNAs observed in the presence of inhibitor
A on the polyacrylamide gel presented in Fig. 2. Extension of
the RNA to this length may position the 5 end of the tran-
script within the guanylylation site (or NDK-similarity region)
(Fig. 7E). Simultaneous binding of the 5 end of the nascent
transcript and guanine nucleotide would cause cotranscrip-
tional formation the GpppGp cap at the 5 end of the mRNA
(Fig. 7F and G). The precise mechanism of guanine nucleotide
transfer is currently unknown. Following guanylylation, the 5
end of the mRNA would be transferred to the SAM binding
site, allowing for cotranscriptional methylation of the guanyly-
lated RNA (Fig. 7H and I). However, methylation of the
mRNA is not essential for elongation, since S-adenosylhomo-
FIG. 6—Continued.
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cysteine does not inhibit transcription but only inhibits cotrans-
criptional methylation of the RSV mRNAs (5) (M. Liuzzi and
R. S. McCollum, unpublished results). The capped and meth-
ylated mRNA is then elongated until the transcriptase encoun-
ters a gene end sequence, where polyadenylation of the 3 end
of the transcript occurs (15, 44). In contrast, the presence of
inhibitor blocks guanylylation (Fig. 7L), preventing further
elongation and resulting in release of short transcripts. Thus,
the action of inhibitor causes the iterative synthesis of short
uncapped transcripts that are detected in the DE81 filter bind-
ing assay and on polyacrylamide gels (Fig. 2) but not in the
poly(A) capture assay since they are not polyadenylated.
Several predictions can be made based on this model. The
length of the RNA as it reaches the guanylylation site and its
sequence are crucial determinants for whether it is subject to
guanylylation and distinguish it from the leader RNA. Thus,
the leader RNA is not capped and is extended as a replication
product without guanylylation of its 5 end (8). Dissection of
the leader region points to elements required for either repli-
cation or transcription (28). In addition, the “switch” from
transcriptase to replicase activity could be the action of a nat-
ural inhibitor of guanylylation, with the result that RNAs con-
taining the leader sequence are elongated past the first (and
probably all) gene start sequence(s). The identity of the mo-
lecular switch remains to be determined but could be the M2-2
protein since the genetic ablation of M2-2 expression greatly
enhances the synthesis of mRNA over antigenome (6).
In conclusion, the RSV polymerase inhibitors described
here represent a novel class of nonnucleoside antiviral agents
with a unique mechanism of action. Our results demonstrate
that the guanylylation activity of the RSV RNP complex is an
attractive target in the search for new anti-RSV agents. Most
importantly, the optimized leads exhibited antiviral activity in
vivo. These novel inhibitors may therefore provide a good
starting point for the development of anti-RSV therapeutics
for the treatment and prevention of RSV infections in humans.
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